The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Akeso’s ivonescimab BTC combination wins China Priority Review after positive Phase III results

Nov 5, 2026 04:19 (3h ago)

Verifying

Akeso received China Priority Review for ivonescimab plus chemotherapy in first-line biliary tract cancer.
HARMONi-GI1 met its overall-survival, progression-free-survival and objective-response-rate endpoints.
Summit announced an ECOG-ACRIN collaboration for the EA2251 Phase II/III BTC study on October 21, 2026.